DLH Holdings Corp. — Form 10-Q Summary
Reporting period: Fiscal second quarter and six months ended March 31, 2024. The quarter and interim financial statements are unaudited. Amounts below are in millions, except per-share data and percentages.
Business context and reporting period
DLH provides technology-enabled health, public health, research, logistics, cyber, and engineering services primarily to U.S. federal agencies. Revenue is heavily concentrated in HHS, the VA, and DoD. The six-month revenue increase was attributed principally to the December 2022 acquisition; quarterly growth reflected public health and IT services, partly offset by national security work moving to small-business set-aside contractors.
Financial performance
| Metric | Three months ended March 31, 2024 | Six months ended March 31, 2024 | Comparable prior period |
|---|---|---|---|
| Revenue | $101.0; up 1.6% | $198.9; up 15.5% | $99.4 quarterly; $172.2 six-month |
| Operating income / margin | $5.9 / 5.9% | $12.8 / 6.4% | $6.0 / 6.0%; $9.9 / 5.7% |
| Net income / margin | $1.8 / 1.8% | $4.0 / 2.0% | $0.8 / 0.8%; $2.4 / 1.4% |
| Diluted EPS | $0.12 | $0.27 | $0.06; $0.16 |
| EBITDA, company-defined non-GAAP | $10.2 | $21.3 | $10.5; $16.8 |
Quarterly operating income was essentially flat year over year. Quarterly net income rose as interest expense and the income-tax provision fell; the tax provision was a benefit in both 2024 periods. For the six months, operating income improved, while interest expense rose $2.3 million, principally due to acquisition financing. Six-month net income benefited from a tax benefit, which management attributed primarily to stock-based compensation as options were exercised.
Cash flow, debt, and liquidity
- Six-month operating cash flow was $10.3 million, versus $6.9 million a year earlier; management cited improved accounts-receivable collections. Capital expenditures were $0.5 million, implying operating cash flow less capital expenditures of approximately $9.8 million.
- Cash was $0.2 million at March 31, 2024. Total available liquidity was $22.7 million, including $22.5 million of unused revolver capacity, net of letters of credit.
- Debt obligations were $170.8 million gross: a $156.8 million term loan and $14.0 million revolver balance. Net of cash, debt was approximately $170.5 million. The company made $5.9 million of voluntary term-loan prepayments in the six-month period and reported compliance with all loan covenants.
- Debt bears interest at SOFR plus 4.1%; the reported floating-rate debt rate was 9.4%. Interest-rate swaps covered $89 million of notional debt. Management estimated that a 1 percentage-point rise in SOFR would increase annual interest expense by approximately $0.8 million.
- Current assets were $57.9 million and current liabilities $56.2 million. Contract assets included in receivables were $21.8 million; no doubtful-account allowance was recorded.
Material changes, outlook, and risks
- Customer concentration: Six-month revenue was HHS 46.1%, VA 35.4%, and DoD 16.7%. Management warns that losing or materially reducing work with a major customer or contract could adversely affect results, cash flows, and financial condition.
- VA contract transition: VA pharmacy and logistics work operated under bridge arrangements while the agency evaluated eight procurements. DLH reported a Chelmsford award decision to an unrelated SDVOSB and said its joint venture was pursuing remedies; a final award decision had not been made. The VA subsequently awarded DLH a sole-source IDIQ effective May 1, 2024, with a $200 million ceiling and initial task orders through July 31, 2024. The contract can extend through April 30, 2025, with certain orders potentially extending performance through October 2025. The ceiling is not guaranteed revenue; future volume depends on orders and procurement outcomes.
- Backlog: Total backlog rose to $736.2 million from $704.8 million at September 30, 2023, while funded backlog fell to $106.9 million from $169.9 million. Backlog is management-estimated and may not convert to revenue; funded amounts depend on government appropriations and tasking.
- Liquidity outlook: Management stated that planned operating cash flow should be sufficient to support operations for 12 months from issuance of the statements. The filing provides no specific financial forecast or formal revenue or earnings guidance.
- Other risks and contingencies: Risks include federal budget and procurement changes, protests, set-aside rules, contract termination or non-renewal, employee retention, debt management, covenant compliance, inflation, and interest rates. DLH reported no litigation it considered reasonably likely to have a material adverse effect and no material risk-factor changes from its prior annual report.
- Unusual items: The prior-year six-month period included $1.7 million of corporate development costs and $180.7 million of acquisition-related investing cash outflow. Goodwill remained $138.2 million, with no impairment-triggering business-condition change identified by management.
Important facts for investors to verify
- Progress, protests, awards, and task-order funding for the VA’s eight CMOP procurements, including the duration and expected volume of the interim IDIQ work.
- Whether the significant decline in funded backlog converts to new appropriations and orders, and how total backlog converts into recognized revenue.
- HHS, VA, and DoD contract retention, recompete outcomes, and the effects of small-business set-aside requirements.
- Debt paydown, revolver availability, covenant headroom, and exposure to floating rates as interest-rate swaps mature.
- Cash conversion and receivables, including the $21.8 million contract-asset balance, alongside the company’s stated 12-month liquidity assessment.